US › Healthcare

Cerus Corporation (CERS)

US · Healthcare · Medical Devices

$2.66+5.14%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$57.4M

Revenue YoY

+9.5%

Net profit

$-2.9M

EPS

$-0.01

EPS estimate

$-0.01

Net margin

-5.1%

EPS came in at -0.01 against a street estimate of -0.01 — a beat of 0.0%.

Key statistics

Market cap

$501.8M

Forward P/E

0.0

P/B

7.17

Book value

$0.35

EPS (TTM)

$-0.03

52-week high

$3.47

52-week low

$1.20

50-day MA

$2.79

200-day MA

$2.39

Beta

1.80

Analyst view

Analysts rate Cerus Corporation a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $5.12.

Shareholding

Insiders

3.61%

Institutions

73.31%

Largest institutional holders

Fund	Stake
BlackRock Inc	10.71%
ARK Investment Management LLC	9.51%
Baker Bros Advisors LP	4.97%
Vanguard Capital Management, LLC	4.04%
D. E. Shaw & Co LP	2.72%
Geode Capital Management, LLC	2.30%
Silvercrest Asset Management Group LLC	2.10%
State Street Corp	2.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cerus Corporation — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.